ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Dec 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-12-06

Reporting Person: Lowenthal Richard E (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-06	Common Stock	M	11876	$8.42	Acquired	4327189	Direct
2024-12-06	Common Stock	M	13789	$1.44	Acquired	3421636	Indirect
2024-12-06	Common Stock	M	11876	$8.42	Acquired	3433512	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-06	Stock Option (right to buy)	$8.42	M	11876	Disposed	2033-01-02	Common Stock (11876)	Direct
2024-12-06	Stock Option (right to buy)	$1.44	M	13789	Disposed	2031-12-13	Common Stock (13789)	Indirect
2024-12-06	Stock Option (right to buy)	$8.42	M	11876	Disposed	2033-01-02	Common Stock (11876)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1296494	Indirect
Common Stock	1198499	Indirect
Common Stock	1347447	Indirect

Footnotes

F1: The Reporting Person is trustee of the trust.

F2: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

F3: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F4: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.